Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies CEO, Others Resign Following Annual Meeting

NEW YORK (GenomeWeb News) – Paul MacLeman, CEO of Australian firm Genetic Technologies, and other members of the firm's board and executive team resigned Tuesday following the firm's annual general meeting.

The resignations came after Chairman Mel Bridges and Director Huw Jones were not re-elected to the firm's board. Those two will leave the board along with Director Greg Brown, who resigned following the results of the voting even though he was re-elected. David Sparling, VP of legal and corporate development for the firm, also tendered his resignation.

GenomeWeb Daily News was unable to receive additional information and comment from Genetic Technologies by the time this article was published. However, the website of Australia's national newspaper, The Australian, reported that Genetic Technologies Founder Mervyn Jacobson had used his 29 percent stake in the firm to block the re-elections of Bridges and Jones.

"Dr. Bridges said it is regrettable that a company with the potential of GTG was unable to reach middle ground with its major shareholder," Genetic Technologies said in a statement posted on its website.

Genetic Technologies sells the BrevaGen breast cancer risk stratification test. The firm recently reported a 50 percent decline in first-quarter revenues.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more